CN104755088A - 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用 - Google Patents

半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用 Download PDF

Info

Publication number
CN104755088A
CN104755088A CN201380057194.2A CN201380057194A CN104755088A CN 104755088 A CN104755088 A CN 104755088A CN 201380057194 A CN201380057194 A CN 201380057194A CN 104755088 A CN104755088 A CN 104755088A
Authority
CN
China
Prior art keywords
compound
galectin
formula
pulmonary fibrosis
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380057194.2A
Other languages
English (en)
Chinese (zh)
Inventor
乌尔夫·尼尔松
哈康·莱弗勒
尼尔·亨德森
塔里克·塞蒂
艾利森·麦金农
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galecto Biotech AB
Original Assignee
Galecto Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2794066A external-priority patent/CA2794066C/en
Priority claimed from US13/832,672 external-priority patent/US9243021B2/en
Application filed by Galecto Biotech AB filed Critical Galecto Biotech AB
Publication of CN104755088A publication Critical patent/CN104755088A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/001—Details of inhalators; Constructional features thereof with means for agitating the medicament using ultrasonic means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201380057194.2A 2012-10-31 2013-10-30 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用 Pending CN104755088A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261720641P 2012-10-31 2012-10-31
US61/720,641 2012-10-31
CA2794066A CA2794066C (en) 2012-10-31 2012-10-31 Galactoside inhibitor of galectins
CA2794066 2012-10-31
CA2795753A CA2795753A1 (en) 2012-10-31 2012-11-15 Novel galactoside inhibitor of galectins
CA2795793 2012-11-15
US13/832,672 2013-03-15
US13/832,672 US9243021B2 (en) 2012-10-31 2013-03-15 Galactoside inhibitor of galectins
PCT/EP2013/072691 WO2014067986A1 (en) 2012-10-31 2013-10-30 Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis

Publications (1)

Publication Number Publication Date
CN104755088A true CN104755088A (zh) 2015-07-01

Family

ID=52686686

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380057194.2A Pending CN104755088A (zh) 2012-10-31 2013-10-30 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用

Country Status (7)

Country Link
EP (2) EP3278805A1 (enExample)
JP (1) JP2015535233A (enExample)
CN (1) CN104755088A (enExample)
CA (1) CA2884802A1 (enExample)
ES (1) ES2817888T3 (enExample)
IN (1) IN2015DN02573A (enExample)
WO (1) WO2014067986A1 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602847A (zh) * 2015-12-18 2018-09-28 格莱克特生物技术公司 多晶型及方法
CN108602848A (zh) * 2015-11-09 2018-09-28 格莱克特生物技术公司 1，1’-硫烷二基-二-β-D-吡喃半乳糖苷作为半乳糖凝集素的抑制剂
CN109071585A (zh) * 2016-03-04 2018-12-21 卡莱克汀科学有限责任公司 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途
CN109563119A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CN109563120A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CN112292386A (zh) * 2018-06-15 2021-01-29 百时美施贵宝公司 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物
CN112672765A (zh) * 2018-06-29 2021-04-16 格莱科斯生物医药公司 结合物
CN114222749A (zh) * 2019-06-24 2022-03-22 格莱克特生物技术公司 3,3′-二脱氧-3,3′-双-[4-(3-氟苯基)-1H-1,2,3-三唑-1-基]-1,1′-磺胺二基-二-β-D-吡喃半乳糖苷的大规模方法
CN115362160A (zh) * 2020-03-31 2022-11-18 格莱克特生物技术公司 用于制备1,2,4,6-四-o-乙酰基-3-叠氮基-3-脱氧-d-吡喃半乳糖苷的大规模方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
ES2784873T3 (es) * 2014-07-09 2020-10-01 Galecto Biotech Ab Novedoso inhibidor galactósido híbrido de galectinas
ES2776255T3 (es) 2015-01-16 2020-07-29 Galecto Biotech Ab Novedoso inhibidor de galactósido de galectinas
CN107406478B (zh) * 2015-01-30 2021-07-27 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
EP3294293B1 (en) * 2015-05-12 2020-11-18 Galecto Biotech AB Once-daily treatment of pulmonary fibrosis
JP6915956B2 (ja) * 2015-05-15 2021-08-11 ガレクト・バイオテック・エイビイ 肺線維症の１日１回の治療
WO2017019770A1 (en) * 2015-07-27 2017-02-02 Wayne State University Compositions and methods relating to galectin detection
CA3062648A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
US11267811B2 (en) 2017-09-27 2022-03-08 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US11072626B2 (en) 2017-10-11 2021-07-27 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
AU2018395417B2 (en) 2017-12-29 2023-07-13 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
BR112020013647A2 (pt) 2018-01-10 2020-12-01 Galecto Biotech Ab novo inibidor galactosídeo de galectinas
AU2019271285B2 (en) 2018-05-17 2024-10-03 Actuate Therapeutics, Inc. Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
WO2020078807A1 (en) 2018-10-15 2020-04-23 Galecto Biotech Ab Prodrug of galactoside inhibitors of galectins
CN113366007A (zh) 2018-10-15 2021-09-07 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂
US11447517B2 (en) 2018-11-21 2022-09-20 Galecto Biotech Ab Galactoside inhibitor of galectins
US12275718B2 (en) 2018-12-06 2025-04-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2020139960A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc Galectin-3 inhibiting c-glycosides
US12275719B2 (en) 2019-03-26 2025-04-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2020210308A1 (en) 2019-04-10 2020-10-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2020248068A1 (en) 2019-06-14 2020-12-17 UNIVERSITé LAVAL Synthesis of 3-azido-3-deoxy-d-galactopyranose
WO2021001528A1 (en) 2019-07-03 2021-01-07 Galecto Biotech Ab Novel galactoside inhibitor of galectins
JP7674275B2 (ja) 2019-07-03 2025-05-09 ガレクト バイオテック エービー ガレクチンの新規なガラクトシド阻害剤
CN114450282A (zh) 2019-07-05 2022-05-06 格莱克特生物技术公司 半乳糖凝集素的新型半乳糖苷抑制剂
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
US12410208B2 (en) 2019-08-09 2025-09-09 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-D-galactopyranoside derivatives
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
EP4021904B1 (en) 2019-08-29 2024-01-03 Idorsia Pharmaceuticals Ltd Alpha-d-galactopyranoside derivatives
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
WO2021195020A1 (en) * 2020-03-23 2021-09-30 G3 Pharmaceuticals, Inc. Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
WO2021226002A1 (en) 2020-05-05 2021-11-11 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
KR20230009433A (ko) 2020-05-11 2023-01-17 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3의 소분자 억제제
US12291522B2 (en) 2020-05-28 2025-05-06 Bristol-Myers Squibb Company Galectin-3 inhibitors
TWI890869B (zh) 2020-10-06 2025-07-21 瑞士商愛杜西亞製藥有限公司 α-D-吡喃半乳糖苷之螺衍生物
TW202233609A (zh) 2020-11-02 2022-09-01 瑞士商愛杜西亞製藥有限公司 2-羥環烷-1-胺甲醯基衍生物
IL304923A (en) 2021-02-09 2023-10-01 Idorsia Pharmaceuticals Ltd History of hydroxyheterocycloalkane-carbamoyl
ES3033422T3 (en) 2021-03-03 2025-08-04 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives
WO2025111704A1 (en) * 2023-12-01 2025-06-05 UNIVERSITé LAVAL Selective inhibitors of galectin-3

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170715B1 (de) 1984-08-09 1988-04-13 Inge Brugger Zerstäubervorrichtung
US5152456A (en) 1989-12-12 1992-10-06 Bespak, Plc Dispensing apparatus having a perforate outlet member and a vibrating device
GB9027234D0 (en) 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
EP0940154B1 (en) 1991-07-02 2007-04-18 Nektar Therapeutics Device for delivering aerosolized medicaments
ATE209053T1 (de) 1996-01-03 2001-12-15 Glaxo Group Ltd Inhaliervorrichtung
DE19726110C2 (de) 1997-06-20 1999-07-22 Draegerwerk Ag Aerosolgenerator für Beatmungssysteme
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE10102846B4 (de) 2001-01-23 2012-04-12 Pari Pharma Gmbh Aerosolgenerator
DE50102690D1 (de) 2001-10-18 2004-07-29 Pari Gmbh Inhalationstherapievorrichtung
AU2002343094A1 (en) * 2001-11-26 2003-06-10 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
DE60235883D1 (de) 2002-08-02 2010-05-20 Pari Pharma Gmbh Vorrichtung zur Erzeugung von Flüssigkeitströpfchen
DE10250625A1 (de) 2002-10-30 2004-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10257381B4 (de) 2002-12-09 2006-09-14 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
WO2006009209A1 (ja) * 2004-07-22 2006-01-26 Kaken Pharmaceutical Co., Ltd. 慢性炎症性肺疾患を予防もしくは治療する薬剤
US8703720B2 (en) 2009-04-28 2014-04-22 Galecto Biotech Ab Galactoside inhibitors of galectins
DE102009026636B4 (de) 2009-06-02 2011-04-14 Pari Pharma Gmbh Verfahren zum Verschweißen einer Membran mit einem Träger bei der Herstellung eines Membranverneblers
JP6031510B2 (ja) * 2011-04-12 2016-11-24 モイライ マトリックス インコーポレイテッド 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALISON C. MACKINNON等: "Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3", 《AM J RESPIR CRIT CARE MED》 *
张志荣等: "《靶向治疗分子基础与靶向药物设计》", 31 December 2005, 科学出版社 *
杨祥良等: "《纳米药物安全性》", 31 January 2010, 科学出版社 *
蒋新国: "《生物药剂学与药物动力学》", 31 January 2009, 高等教育出版社 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602848B (zh) * 2015-11-09 2022-01-18 格莱克特生物技术公司 1，1’-硫烷二基-二-β-D-吡喃半乳糖苷作为半乳糖凝集素的抑制剂
CN108602848A (zh) * 2015-11-09 2018-09-28 格莱克特生物技术公司 1，1’-硫烷二基-二-β-D-吡喃半乳糖苷作为半乳糖凝集素的抑制剂
CN108602847A (zh) * 2015-12-18 2018-09-28 格莱克特生物技术公司 多晶型及方法
CN109071585A (zh) * 2016-03-04 2018-12-21 卡莱克汀科学有限责任公司 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途
CN109071585B (zh) * 2016-03-04 2022-08-16 卡莱克汀科学有限责任公司 预防和治疗半乳糖凝集素相关疾病的硒代半乳糖苷化合物及其用途
CN109563119A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CN109563120A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CN109563120B (zh) * 2016-07-12 2022-12-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CN112292386A (zh) * 2018-06-15 2021-01-29 百时美施贵宝公司 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物
CN112292386B (zh) * 2018-06-15 2024-06-11 百时美施贵宝公司 作为半乳凝素-3抑制剂的基于四氢吡喃的硫代二糖模拟物
CN112672765A (zh) * 2018-06-29 2021-04-16 格莱科斯生物医药公司 结合物
CN114222749A (zh) * 2019-06-24 2022-03-22 格莱克特生物技术公司 3,3′-二脱氧-3,3′-双-[4-(3-氟苯基)-1H-1,2,3-三唑-1-基]-1,1′-磺胺二基-二-β-D-吡喃半乳糖苷的大规模方法
CN115362160A (zh) * 2020-03-31 2022-11-18 格莱克特生物技术公司 用于制备1,2,4,6-四-o-乙酰基-3-叠氮基-3-脱氧-d-吡喃半乳糖苷的大规模方法

Also Published As

Publication number Publication date
CA2884802A1 (en) 2014-05-08
WO2014067986A1 (en) 2014-05-08
IN2015DN02573A (enExample) 2015-09-11
EP2914269B1 (en) 2020-07-29
WO2014067986A8 (en) 2016-04-14
ES2817888T3 (es) 2021-04-08
JP2015535233A (ja) 2015-12-10
EP3278805A1 (en) 2018-02-07
EP2914269A1 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
CN104755088A (zh) 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用
US9580456B2 (en) Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
RU2693382C2 (ru) Лечение заболевания дыхательной системы
US11564925B2 (en) Treatment of respiratory diseases
US9301994B2 (en) LIGHT inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
JP6820743B2 (ja) 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）
JP2010539083A (ja) 細胞内カルシウムを調節する化合物
CN117180280A (zh) 赖氨酰氧化酶样2抑制剂的用途
CN108367012B (zh) 自体免疫性和自身炎症性疾病的治疗
WO2011159633A1 (en) Inhalable formulations of lysophosphatdic acid receptor antagonists
CA2575932A1 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
US20170079988A1 (en) Ciclesonide for the treatment of airway disease in horses
JP3691459B2 (ja) 粉末状吸入剤組成物
US20060148712A1 (en) Monocyte chemoattractant activity of galectin-3
CA2795753A1 (en) Novel galactoside inhibitor of galectins
CN101005855A (zh) 治疗由ccr2介导的疾病或紊乱的方法
JP5555255B2 (ja) 呼吸器疾患の治療のためのスルホンアミド化合物
AU2013322342A1 (en) Therapeutic for Treating Inflammatory Lung Disorders
JP2013522295A (ja) 気道炎症及び粘液線毛輸送機能異常治療用のエアロゾル化したダプソン
KR20230116786A (ko) 만성 폐쇄성 폐질환, 천식, 폐렴, 기관지염, 낭포성 섬유증, 폐부종, 간질성 폐 질환, 사르코이드증, 특발성 폐섬유증, 급성 호흡곤란 증후군 및 폐동맥 고혈압을 치료하기 위한 방법 및 조성물
Nabe et al. Intratracheal dosing with disodium cromoglycate inhibits late asthmatic response by attenuating eicosanoid production in guinea pigs
WO2021154917A1 (en) Methods of using momelotinib to treat joint inflammation
CN117562915A (zh) 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用
Abbas et al. BRITISH BIOMEDICAL BULLETIN
US20220054509A1 (en) Methods of treatment for disease from coronavirus exposure

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150701